Leuprolide Acetate Market Size & Share, by Product (Vials, Prefilled Syringes, Lyophilized Powder); Application (Cancer, Endometriosis, Radical Prostatectomy, Hormone Therapy, Central Precocious Puberty, Uterine Fibroids); Route of Administration (Intradermal, Intramuscular, Subcutaneous); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5156
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024 - 2036

Leuprolide Acetate Market size was over USD 2.14 Billion in 2023 and is anticipated to reach USD 5.09 Billion by 2036, witnessing around 6.9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of leuprolide acetate is estimated at USD 2.28 Billion. The reason behind the growth is impelled by the growing cases of cancer across the globe. Cancer is currently the third biggest cause of mortality which is majorly caused owing to the combined effects of genetic differences, environmental variables, and dietary decisions.

Advanced cancer patients may use leuprolide acetate as a palliative treatment since it is a well-known luteinizing hormone-releasing hormone (LHRH) agonist in prostate cancer. To grow and spread, the majority of prostate cancer forms require the hormone testosterone. According to estimates, in 2040, there will be more than 28 million new instances of cancer worldwide.

The growing prevalence of uterus fibroids are believed to fuel the leuprolide acetate market . For instance, in women of reproductive age, fibroids are the most prevalent type of pelvic tumor, and by the time they are 50 years old, more than 50% of women have fibroids. 

Leuprolide acetate is the most popular drug for treating uterine fibroids in women since it has been approved for reducing the size of fibroids.


Leuprolide Acetate Market Overview
Get more information on this report: Request Free Sample PDF

Leuprolide Acetate Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Demand for IVF Treatment – It is expected that the growing incidence of infertility owing to lifestyle changes, may drive market growth. 
  • Leuprolide acetate injection is a synthetic gonadotropin-releasing hormone that can be used to mature the eggs for retrieval. Moreover, lupron is an injectable fertility drug that is in the category of GnRH agonists which reduces the production of estrogen and progesterone by the ovaries. Over the past five years, IVF cycles have climbed at a pace of over 23%, and India is now ranked third globally for IVF procedures.
  • Growing Geriatric Population- Hormone-related disorders are more common in older people, and the rising elderly population is expected to increase the demand for leuprolide acetate since it is used to manage hormonal imbalances.
  • The number of individuals in the world who are 60 or older will reach over 2 billion by 2050.

Challenges

  • Risk of Potential Side Effects- Leuprolide acetate may cause several side effects such as breast swelling or tenderness, hot flashes, increased bone pain, increased difficulty passing urine, or an aggravation of nerve symptoms, which may hamper the market growth.
  • Stringent Price Control Policies
  • Availability of Alternative Treatments

Leuprolide Acetate Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

6.9%

Base Year Market Size (2023)

USD 2.14 Billion

Forecast Year Market Size (2036)

USD 5.09 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Leuprolide Acetate Segmentation

Product (Vials, Prefilled Syringes, Lyophilized Powder)

The prefilled syringes segment in the leuprolide acetate market is estimated to gain a robust revenue share of 48% in the coming years owing to the benefits offered by prefilled syringes. Prefilled syringes provide a high degree of accuracy since they are convenient to use and maintain the drug's potency, strength, and purity throughout its shelf life. These syringes make the procedure of giving a medication product to a patient safer, faster, and simpler and can reduce the cost. Moreover, LUPRON DEPOT is offered as prefilled dual-chamber syringes, which are, disposable syringes filled with a prescribed unit amount of medication.

Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)

Leuprolide acetate market from the online pharmacy segment is set to garner a notable share shortly on the account of growing demand for online shopping. The preference of people is shifting toward online shopping to purchase medicinal drugs through online pharmacies since it saves time and effort. Moreover, an online pharmacy guarantees quick medication search, selection, and ordering, and also gives customers anonymity, which has made it a popular method of purchase for many customers. This could lead to an increase in demand for medications including leuprolide acetate through online channels.

Our in-depth analysis of the global leuprolide acetate market includes the following segments:

    Product

  • Vials
  • Prefilled Syringes
  • Lyophilized Powder

    Route of Administration

  • Intradermal
  •  Intramuscular
  •  Subcutaneous

   Application

  • Endometriosis
  •  Radical Prostatectomy
  • Hormone Therapy
  •  Central Precocious Puberty
  • Uterine Fibroids
  • Cancer

    Distribution Channel

  • Hospital Pharmacy
  •  Retail Pharmacy
  • Online Pharmacy

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Leuprolide Acetate Industry- Regional Synopsis

North American Market Forecast

Leuprolide acetate market in North America is predicted to account for the largest share of 40% by 2036 impelled by the growing spending in healthcare. This would improve medical access which will drive more patients to seek the diagnosis of several diseases such as prostate cancer, and fertility issues in the region, leading to higher demand for leuprolide acetate. In 2021, health spending in the US increased by over 2%.

European Market Statistics

The Europe leuprolide acetate market is estimated to be the second largest, during the forecast timeframe led by advancements in medical care. As a result more effective leuprolide acetate is being developed in the region which increased its adoption to manage conditions such as fertility issues, and prostate cancer.

Research Nester
Leuprolide Acetate Market Regional
Get more information on this report: Request Free Sample PDF

Companies Dominating the Leuprolide Acetate Market

    • Ferring B.V.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Sun Pharmaceutical Industries Ltd.
    • Beijing Biote Pharmaceutical Co., Ltd.
    • Anhui Anke Bioengineering (Group) Co., Ltd.
    • AbbVie Inc.
    • Merck & Co., Inc.
    • Taj Pharmaceuticals Limited.
    • Zydus Group
    • Cipla Inc.

In the News

  • Eugia Pharma Specialties Limited received approval from the US Food and Drug Administration (USFDA) to produce and sell injectable leuprolide acetate which is employed to treat the symptoms of advanced prostate cancer.
  • Cipla Inc. introduced Leuprolide Acetate Injection Depot 22.5mg to offer patients in the US high-quality, inexpensive treatments, and enable access to top-notch therapies. Further, it is provided as lyophilized microspheres in a single dose vial as part of a kit that also includes MIXJECT transfer device and a prefilled syringe.

Author Credits:  Radhika Pawar


  • Report ID: 5156
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of leuprolide acetate is estimated at USD 2.28 Billion.

The leuprolide acetate market size was over USD 2.14 Billion in 2023 and is anticipated to reach USD 5.09 Billion by 2036, witnessing around 6.9% CAGR during the forecast period i.e., between 2024-2036. Growing cases of cancer across the globe and the growing prevalence of uterus fibroids are the major factors driving the growth of the market.

North America industry is predicted to account for the largest share of 40% by 2036, impelled by growing spending in healthcare in the region.

Ferring B.V., Sun Pharmaceutical Industries Ltd., Beijing Biote Pharmaceutical Co., Ltd., Anhui Anke Bioengineering (Group) Co., Ltd., AbbVie Inc., Merck & Co., Inc., Taj Pharmaceuticals Limited., Zydus Group, Cipla Inc.
Leuprolide Acetate Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample